Search

Your search keyword '"Dai, Dong-Qiu"' showing total 178 results
Start Over Author "Dai, Dong-Qiu" Search Limiters Full Text
178 results on '"Dai, Dong-Qiu"'

13. The functional role of Pescadillo ribosomal biogenesis factor 1 in cancer

Author

Li, Yong-Zhi, Zhang, Cheng, Pei, Jun-Peng, Zhang, Wan-Chuan, Zhang, Chun-Dong, and Dai, Dong-Qiu

Subjects
signaling pathway, treatment, Oncology, proliferation, cancer, Review, PES1
Abstract

Tumors are neogrowths formed by the growth of normal cells or tissues through complex mechanisms under the influence of many factors. The occurrence and development of tumors are affected by many factors. Pescadillo ribosomal biogenesis factor 1 (PES1) has been identified as a cancer-related gene. The study of these genes may open up new avenues for early diagnosis, treatment and prognosis of tumors. As a nucleolar protein and part of the Pes1/Bop1/WDR12 (PeBoW) complex, PES1 is involved in ribosome biogenesis and DNA replication. Many studies have shown that high expression of PES1 is often closely related to the occurrence, proliferation, invasion, metastasis, prognosis and sensitivity to chemotherapeutics of various human malignant tumors through a series of molecular mechanisms and signaling pathways. The molecules that regulate the expression of PES1 include microRNA (miRNA), circular RNA (circRNA), c-Jun, bromodomain-containing protein 4 (BRD4) and nucleolar phosphoprotein B23. However, the detailed pathogenic mechanisms of PES1 overexpression in human malignancies remains unclear. This article summarizes the role of PES1 in the carcinogenesis, prognosis and treatment of multiple tumors, and introduces the molecular mechanisms and signal transduction pathways related to PES1.

Published
2022
Full Text
View/download PDF

47. Downregulation and DNA methylation of ECRG4 in gastric cancer

Author

Deng,Peng, Chang,Xiao-Jing, Gao,Zi-Ming, Xu,Xiao-Yang, Sun,An-Qi, Li,Kai, Dai,Dong-Qiu, Deng,Peng, Chang,Xiao-Jing, Gao,Zi-Ming, Xu,Xiao-Yang, Sun,An-Qi, Li,Kai, and Dai,Dong-Qiu

Abstract

Peng Deng,1 Xiao-Jing Chang,1 Zi-Ming Gao,2 Xiao-Yang Xu,1 An-Qi Sun,2 Kai Li,2 Dong-Qiu Dai1 1Department of Gastrointestinal Surgery and Cancer Center, The Fourth Affiliated Hospital of China Medical University, Shenyang, China; 2Department of Surgical Oncology and General Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China Background: Esophageal cancer-related gene 4 (ECRG4) is a novel candidate tumor suppressor gene. Our study investigated the expression and function of ECRG4 in gastric cancer and highlighted the role of DNA hypermethylation at the promoter in silencing the ECRG4 expression. Methods: The GSE63089 data set was obtained from the Gene Expression Omnibus and analyzed for differentially expressed genes. Carcinoma and para-carcinoma tissues of 102 patients with gastric cancer were collected from January 2010 to July 2011. Immunohistochemistry, real-time polymerase chain reaction (PCR), and western blot analyses were performed to evaluate the expression of ECRG4. After measuring the change in the level of ECRG4 expression, CCK-8, Transwell, and flow cytometric cell cycle assays were performed. In addition, methylation-specific PCR was performed to detect the methylation state of ECRG4, and 5-aza-2'-deoxycytidine was used for demethylation of ECRG4. All statistical analyses were performed using the SPSS 17.0 software. Results: We found that ECRG4 expression was downregulated in gastric cancer, and this was closely related to lymph node metastasis. After ECRG4 was silenced using a specific small interfering RNA, the BGC-823 cell line became highly aggressive and proliferative. In addition, we verified whether downregulation of ECRG4 was highly correlated with DNA methylation of the ECRG4 promoter and found that the demethylating agent 5-aza-2'-deoxycytidine could effectively enhance ECRG4 expression. Conclusion: The aberrant expression of ECRG4 is associated with hypermethylation in the promoter region and p

Published
2018

50. Prognostic and Predictive Model for Stage II Colon Cancer Patients With Nonemergent Surgery

Author

Zhang, Chun-Dong, Wang, Ji-Nan, Sui, Bai-Qiang, Zeng, Yong-Ji, Chen, Jun-Qing, and Dai, Dong-Qiu

Subjects
Adult, Aged, 80 and over, Male, Time Factors, Adolescent, Age Factors, Observational Study, Kaplan-Meier Estimate, Middle Aged, Prognosis, Young Adult, Sex Factors, Chemotherapy, Adjuvant, Colonic Neoplasms, Humans, Lymph Node Excision, Female, Prospective Studies, Neoplasm Metastasis, Research Article, Aged, Neoplasm Staging, Retrospective Studies
Abstract

No ideal prognostic model has been applied to clearly identify which suitable high-risk stage II colon cancer patients with negative margins undergoing nonemergent surgery should receive adjuvant chemotherapy routinely. Clinicopathologic and prognostic data of 333 stage II colon cancer patients who underwent D2 or D3 lymphadenectomy during nonemergent surgery were retrospectively analyzed. Four pathologically determined factors, including adjacent organ involvement (RR 2.831, P = 0.001), histologic differentiation (RR 2.151, P = 0.009), lymphovascular invasion (RR 4.043, P

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results